NuProbe utilizes molecular engineering and scientific expertise to capture disease signatures with high sensitivity and multiplexing capability, enabling early detection and treatment of patients' illnesses. The company's innovative approach in precision diagnostics aims to improve outcomes and reduce costs by detecting, treating, and curing diseases at an earlier stage. Founded in 2016 and based in Houston, Texas, NuProbe focuses on non-invasive early detection of rare genetic variants in patients, addressing one of the world's greatest challenges in healthcare.